IMBRUVICA Drug Patent Profile

Which patents cover Imbruvica, and when can generic versions of Imbruvica launch?

Imbruvica is a drug marketed by Pharmacyclics Llc and is included in three NDAs. There are fifty-seven patents protecting this drug and four Paragraph IV challenges.

This drug has four hundred and ninety-one patent family members in fifty countries.

The generic ingredient in IMBRUVICA is ibrutinib. There are sixteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ibrutinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Imbruvica

Imbruvica was eligible for patent challenges on November 13, 2017.

There have been twenty patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are six tentative approvals for the generic drug (ibrutinib), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for IMBRUVICA

International Patents:	491
US Patents:	57
Applicants:	1
NDAs:	3
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for IMBRUVICA

Paragraph IV (Patent) Challenges for IMBRUVICA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
IMBRUVICA	Capsules	ibrutinib	70 mg	205552	1	2018-12-14
IMBRUVICA	Tablets	ibrutinib	280 mg and 420 mg	210563	1	2018-12-14
IMBRUVICA	Tablets	ibrutinib	560 mg	210563	1	2018-11-05
IMBRUVICA	Capsules	ibrutinib	140 mg	205552	8	2017-11-13

US Patents and Regulatory Information for IMBRUVICA

IMBRUVICA is protected by eighty-eight US patents and five FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmacyclics Llc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-001	Nov 13, 2013		RX	Yes	Yes					Y
Pharmacyclics Llc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-004	Feb 16, 2018		DISCN	Yes	No					Y
Pharmacyclics Llc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-003	Feb 16, 2018		RX	Yes	Yes					Y
Pharmacyclics Llc	IMBRUVICA	ibrutinib	SUSPENSION;ORAL	217003-001	Aug 24, 2022		RX	Yes	Yes

International Patents for IMBRUVICA

When does loss-of-exclusivity occur for IMBRUVICA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Dominican Republic

Ecuador

Eurasian Patent Organization

European Patent Office

Guatemala

Hong Kong

Israel

Japan

Jordan

Malaysia

Mexico

Morocco

New Zealand

Peru

Philippines

Russian Federation

Singapore

South Africa

South Korea

Taiwan

Tunisia

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering IMBRUVICA around the world.

Country	Patent Number	Title	Estimated Expiration
Singapore	10201809111X	THE USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)
Japan	5994051
New Zealand	772688	The use of inhibitors of bruton’s tyrosine kinase (btk)
Japan	2023162162	ブルトン型チロシンキナーゼ阻害剤の結晶形態 (CRYSTALLINE FORMS OF BRUTON TYROSINE KINASE INHIBITOR)

Supplementary Protection Certificates for IMBRUVICA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2529621	C20170010 00279	Estonia		PRODUCT NAME: IBRUTINIIB;REG NO/DATE: EU/1/14/945 07.07.2015
2201840	601	Finland
2201840	233 5006-2015	Slovakia		PRODUCT NAME: IBRUTINIB; REGISTRATION NO/DATE: EU/1/14/945 20141023
2529621	C20170010 00272	Estonia		PRODUCT NAME: IBRUTINIIB;REG NO/DATE: EU/1/14/945 23.10.2014

Investment Scenario, Market Dynamics, and Financial Trajectory for IMBRUVICA (Ibrutinib)

Last updated: February 3, 2026

Summary

IMBRUVICA (ibrutinib) is a breakthrough targeted therapy developed by Janssen Pharmaceuticals, primarily indicated for various B-cell malignancies such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström’s macroglobulinemia (WM). As of 2023, IMBRUVICA is among the top-selling oncology drugs globally, with a revenue of approximately $7.9 billion in 2022. The drug’s market position depends on factors like evolving treatment landscapes, patent protections, pipeline developments, and regulatory policies.

This article analyzes the investment landscape, market dynamics, and financial trajectory, providing clarity on growth prospects and risks associated with IMBRUVICA’s positioning and future revenue streams.

---

1. Market Overview and Demand Drivers

1.1 Global Market Size and Growth

Indicator	2022 Estimate	2023 Projection	CAGR (2023-2028)	Source
Market Value for BTK Inhibitors (all indications)	$16.2 billion	$20.3 billion	6.8%	[1]
IMBRUVICA Sales Revenue	~$7.9 billion	~$8.2 billion	Stable/Moderate growth	Company reports

Key markets:

Region	2022 Revenue	Share of total revenue	Key trends
North America	~$6.0 billion	76%	Dominant; high adoption, mature market
Europe	~$1.2 billion	15%	Growing access, competitive dynamics
Other (Asia, ROW)	~$0.7 billion	9%	Emerging markets, limited access

1.2 Indications and Treatment Adoption Trends

Major indications:

Indication	2022 Revenue	% of Total	Key Growth Drivers
CLL/SLL	~$5.9 billion	75%	Increased use in earlier lines, combination therapies
MCL	~$1.1 billion	14%	Expanding approval for treatments
WM	~$0.5 billion	6%	Stable, niche indication
Other	~$0.4 billion	5%	Emerging indications

Demand drivers include:

• Growing prevalence of B-cell malignancies.
• Increasing adoption of oral targeted therapies.
• Approval of combination regimens extending indications.
• Positive real-world outcomes encouraging earlier line use.

---

2. Market Dynamics and Competitive Landscape

2.1 Competitive Environment

Competitor	Key Drugs	Market Share (2022)	Strengths	Threats
Acalabrutinib (Calquence, AstraZeneca)	Acalabrutinib	~15%	Fewer off-target effects	Potential efficacy gaps
Zanubrutinib (Brukinsa, BeiGene)	Zanubrutinib	~10%	Better tolerability profile	Limited approval for some indications
Others	Various	Remaining	Differentiation by tolerability	Competitive pressure

2.2 Patent Landscape and Intellectual Property

Patent Expiry	Territory	Indication	Impact	Sources
2027-2029	US/EU	Composition of matter	Patent cliff approaching	[2]
2030+	EU/US	Formulations, methods	Potential extensions	[3]

Implication: Patent expiration could lead to generic entry, reducing revenue margins, unless novel formulations or indications are secured.

2.3 Regulatory and Policy Factors

• Pricing and Reimbursement: Increasing pressure on drug prices in the U.S. and Europe may impact margins.
• Orphan Drug and Fast-Track Designations: Extended exclusivity and faster approvals for new indications or formulations.
• Manufacturing and Supply Chain Dynamics: Sovereign risk, raw material costs, especially for active pharmaceutical ingredients (API).

---

3. Clinical Pipeline and Innovation

Development Stage	Indications	Expected Launch Year	Potential Impact	Source
Registration trials	CHRONOS-3 (MCL) + CLL combinations	2024-2025	Extended label, broader patient base	[4]
Early-stage	Multiple myeloma, solid tumors	2024+	Diversification, revenue expansion	Clinical trial registries

Pipeline Advantages:

• Potential to prolong patent exclusivity.
• Increased line approvals strengthen market position.
• Combination strategies with immunotherapies.

---

4. Financial Trajectory and Investment Outlook

4.1 Revenue Growth Projections

Year	Estimated Revenue	Assumptions	Source
2023	~$8.2 billion	Stable demand, no major patent cliff	Company guidance
2024	~$8.5 billion	New indications approved	Forecasts based on pipeline data
2025	~$9.2 billion	Market penetration of pipeline drugs	Analyst estimates
2028	~$10.8 billion	CAGR ~7%	Industry CAGR, pipeline impact

4.2 Profitability and Margin Projections

Metric	2022	2023	2028	Comments
Gross Margin	80%	80%	78%	Slight decline expected with patent expiry
Operating Margin	60%	58%	55%	Increased R&D, marketing costs
Net Profit Margin	50%	48%	45%	Competitive pricing pressures

4.3 Key Investment Risks

Risk Factor	Description	Mitigation Strategies
Patent expiration	Revenue decline post-2027	Pipeline expansion, lifecycle management
Competition	Newer BTK inhibitors or alternative therapies	Strategic alliances, pipeline innovation
Regulatory shifts	Price controls, reimbursement cuts	Early engagement, value-based pricing approaches
Market saturation	Limited growth in mature markets	Expansion into new indications, geographies

---

5. Comparative Analysis with Similar Oncology Drugs

Aspect	IMBRUVICA	Calquence (Acalabrutinib)	Zanubrutinib
Approval Year	2013	2019	2019
Peak Sales (2022)	~$7.9 billion	~$700 million	~$900 million
Patent Expiry	2027-2029	2031	2030
Cost per Year (Approximate)	$150K	$140K	$135K
Indications	CLL, MCL, WM	CLL, MCL	CLL, MCL

Observation: IMBRUVICA maintains market leadership due to longer market presence and wider indication approval, but facing increasing competition.

---

6. Key Policy and External Influences

Policy Aspect	Effect on IMBRUVICA	Notes
Patent Law & Exclusivity	Extended protection until late 2020s	Patent filings and litigations
Reimbursement Policies	Potential pricing pressures	Payer scrutiny increasing
International Access	Variable (developing vs developed countries)	Trade policies influence pricing, supply

---

Conclusion: Investment Outlook and Strategic Recommendations

IMBRUVICA’s established market presence, continuous pipeline development, and expanding indication portfolio support its revenue stability through the mid-2020s. However, impending patent cliffs, increasing competition, and regulatory pressures introduce risks to sustained growth. Investors should consider:

• Medium-Term Growth: Leverages pipeline approvals and expansion into new indications.
• Long-Term Risks: Patent expiration and competitive threats necessitate proactive lifecycle management.
• Strategic Focus Areas: Investment in pipeline innovation, strategic alliances, and market expansion.

---

Key Takeaways

• IMBRUVICA remains a dominant BTK inhibitor with projected revenues exceeding $8 billion through 2023.
• Market dynamics favor continued growth but face potential challenges from patent expiries and competition.
• Pipeline expansion and new indications are vital to maintaining market share.
• Revenue growth is forecasted at approximately 7% CAGR until 2028, with margins gradually declining due to competitive and patent-related pressures.
• Strategic investors should monitor patent expiration timelines, pipeline advancements, regulatory policies, and competitive entries.

---

FAQs

Q1. When are the primary patents for IMBRUVICA set to expire?
A: Patents mainly expire between 2027 and 2029 in the US and EU, after which generic competition may affect revenues.

Q2. How does IMBRUVICA compare to its competitors?
A: IMBRUVICA leads market share due to early market entry and broader approvals, but competitors like acalabrutinib and zanubrutinib are gaining traction with potentially improved tolerability profiles.

Q3. What are the prospects for pipeline-driven revenue expansion?
A: High, given ongoing trials for new indications and combination therapies expected to launch between 2024 and 2025, potentially adding new revenue streams.

Q4. How will regulatory policies influence IMBRUVICA’s future?
A: Increased price regulation and reimbursement constraints could pressure margins, making value-based pricing strategies essential.

Q5. What are the key risks for investors in IMBRUVICA?
A: Patent expiries, competitive launches, regulatory pricing controls, and market saturation pose significant risks.

---

References

[1] EvaluatePharma, 2023. Global Oncology Market Forecast.
[2] PatentScope, WIPO, 2022. Patent Landscape for BTK Inhibitors.
[3] US Patent and Trademark Office, 2023. Patent Expiry Calendar.
[4] ClinicalTrials.gov, 2023. Ongoing and Upcoming Trials for Ibrutinib.